← Leaderboards
Jean Marie Tersak
Children'S Hosp Pittsburgh/Upmc Hlth Sys
$6,296
Attributed
$6,296
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$6,296 · 3
By mechanism
M01$6,296 · 3
Top collaborators
No co-investigators on record.
Most similar at Children'S Hosp Pittsburgh/Upmc Hlth Sys
Same institution · by research overlap
- Dorothy J Becker$40,929,090
- Silva A Arslanian$10,512,392
- Ellen R. Wald$8,036,977
- Robert H Squires$25,005,236
- Nina F Schor$9,201,297
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsChildrenClinical ResearchHuman SubjectHuman Therapy EvaluationPatient Oriented ResearchPharmacokineticsNeuroblastomaPediatric Neoplasm /CancerImmunocytochemistryImmunopharmacologyImmunotherapyInterleukin 2Monoclonal AntibodyMyoclonusBone MarrowNeoplasm /Cancer ChemotherapyChimeric ProteinsNeoplasm /Cancer ImmunotherapyClinical Trial Phase IDosage
Grant awards (4)
RITUXIMAB IN THE TRMT OF OPSOCLONUS-MYOCLONUS IN CHILDREN WITH NEUROBLASTOMA$2,657
M01 · FY2005 · RR
COG: ANBL0321: A PHASE II STUDY OF FENRETINIDE (NSC#374551, IND #40294) IN CHILD$797
M01 · FY2005 · RR
ADVL0018: A Phase I Trial of the HU14.18-IL2 Fusion Protein in Children with$2,084
M01 · FY2004 · RR
Rituximab in the Treatment of Opsoclonus-Myoclonus in Children with Neuroblastom$758
M01 · FY2004 · RR